Safety and immunogenicity of a respiratory syncytial virus prefusion F protein (RSVPreF3) candidate vaccine in older Japanese adults: A phase I, randomized, observer-blind clinical trial-Reference-Cited by-同舟云学术

Safety and immunogenicity of a respiratory syncytial virus prefusion F protein (RSVPreF3) candidate vaccine in older Japanese adults: A phase I, randomized, observer-blind clinical trial

Published:2023-03 Issue:2 Volume:61 Page:261-269
ISSN:2212-5345
Container-title:Respiratory Investigation
language:en
Short-container-title:Respiratory Investigation

Author:

Kotb Shady,Haranaka Miwa^ORCID,Folschweiller Nicolas^ORCID,Nakanwagi Phoebe,Verheust Céline,De Schrevel Nathalie^ORCID,David Marie-Pierre,Mesaros Narcisa,Hulstrøm Veronica

Funder

GlaxoSmithKline

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine

Reference28 articles.

1. Respiratory syncytial virus infection in adults;Nam;BMJ,2019

2. Strategic priorities for respiratory syncytial virus (RSV) vaccine development;Anderson;Vaccine,2013

3. Secretory expression and purification of respiratory syncytial virus G and F proteins in human cells;Jadhao,2016

4. Expression of the F glycoprotein of respiratory syncytial virus by a recombinant vaccinia virus: comparison of the individual contributions of the F and G glycoproteins to host immunity;Olmsted;Proc Natl Acad Sci U S A,1986

5. Seasonal incidence of medically attended respiratory syncytial virus infection in a community cohort of adults ≥50 years old;McClure;PLoS One,2014

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety and immunogenicity of an mRNA-based RSV vaccine in Japanese older adults aged ≥60 years: A phase 1, randomized, observer-blind, placebo-controlled trial;Respiratory Investigation;2024-11

2. Efficacy, Safety, and Immunogenicity of Subunit Respiratory Syncytial Virus Vaccines: Systematic Review and Meta-Analysis of Randomized Controlled Trials;Vaccines;2024-08-02

3. A Randomized, Double‐Blind, Placebo‐Controlled, Phase 1 Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Single Vaccination of Ad26.RSV.preF‐Based Regimen in Japanese Adults Aged 60 Years and Older;Influenza and Other Respiratory Viruses;2024-06

4. Efficacy, immunogenicity and safety of respiratory syncytial virus prefusion F vaccine: systematic review and meta-analysis;BMC Public Health;2024-05-06

5. Respiratory Syncytial Virus Vaccines: Analysis of Pre-Marketing Clinical Trials for Immunogenicity in the Population over 50 Years of Age;Vaccines;2024-03-25